Multiple Endocrine Neoplasia Type 1
12
5
6
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
8.3%
1 terminated out of 12 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
Familial Investigations of Childhood Cancer Predisposition
Natural History Study of Parathyroid Disorders
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor